Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1073-67-2 | MDL No. : | MFCD00000632 |
Formula : | C8H7Cl | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | KTZVZZJJVJQZHV-UHFFFAOYSA-N |
M.W : | 138.59 | Pubchem ID : | 14085 |
Synonyms : |
|
Num. heavy atoms : | 9 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 0.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 41.54 |
TPSA : | 0.0 Ų |
GI absorption : | Low |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -4.49 cm/s |
Log Po/w (iLOGP) : | 2.27 |
Log Po/w (XLOGP3) : | 3.74 |
Log Po/w (WLOGP) : | 2.87 |
Log Po/w (MLOGP) : | 3.44 |
Log Po/w (SILICOS-IT) : | 3.27 |
Consensus Log Po/w : | 3.12 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -3.48 |
Solubility : | 0.0456 mg/ml ; 0.000329 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.43 |
Solubility : | 0.0512 mg/ml ; 0.00037 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -3.43 |
Solubility : | 0.0515 mg/ml ; 0.000372 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 2.0 |
Synthetic accessibility : | 1.31 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P501-P261-P270-P210-P271-P264-P280-P370+P378-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330-P302+P352+P312-P304+P340+P312-P403+P235 | UN#: | N/A |
Hazard Statements: | H302+H312+H332-H315-H319-H227 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
89% | Stage #1: With 1,3-dibromo-5,5-dimethylimidazolidine-2,4-dione In water at 60℃; for 1 h; Stage #2: for 1 h; Reflux |
In a 25 mL reaction flask, add 3 mL of water and 30 μL of Tween,0.5 mmol of chlorostyrene and 0.75 mmol of DBH reacted at 60 °C for 1 h.After the reaction was completed, the water was swirled, 3 mL of ethanol was added, and 0.75 mmol of thiourea was added. The reaction was refluxed for 1 h. After the reaction was completed, ethanol was spin-dried.Ethyl acetate was added to dissolve, and saturated saline solution was added for extraction.The organic phase was concentrated and column chromatography gave 94 mg of a white solid with a yield of 89percent. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
60% | With potassium permanganate; sodium hydroxide In water at 70℃; for 0.5 h; | General procedure: The aryl styrene 0.2mol, 0.4mol sodium hydroxide, water 80mL added to 500mL round bottom flask, heated to 70 ° C, potassium permanganate 0.5mol within 0.5h added in batches after 10min and then reused Ethanol 50mL will notThe reaction of potassium permanganate destruction, the reaction solution was suction filtered, the filtrate was retained, most of the water was distilled off under reduced pressure, the concentrated filtrate was acidified with concentrated hydrochloric acid, and then extracted with dichloromethane to remove the solvent, cooled to give a light The yellow solid was recrystallized from ethanol to give 2-aryl-2-oxoacetic acid.According to General Method 1, 2-(4-chlorophenyl)-2-oxoacetic acid was obtained as a white powder with a yield of 60.0percent. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
52% | Stage #1: With magnesium In tetrahydrofuran Stage #2: at -45 - 20℃; for 3 h; |
Vinylphenylboronic acid was prepared according to the procedurein literature [14]. A solution of 4-vinylphenylmagnesiumchloride (prepared from 0.414 g of magnesium powder and2.00 g (14.4 mmol) of 4-chlorostyrene) in 20 mL of anhydrousTHF was added dropwise to a solution of trimethyl borate(2.54 g, 24.5 mmol) in 40 mL of anhydrous THF at −45 °C.Upon addition, the mixture was slowly warmed to room temperature over 3 h and then quenched with 50 mL of 3 M HCl withstirring. The organic layer was set aside, and the aqueous layer was extracted with diethyl ether (2 × 20 mL). The combined organic phases were evaporated until dried and 40 mL of water was added. The reaction mixture was heated until it boils anddecanted. The residual solid was treated with an additional 40 mL of water, heated until it boils, and decanted again. Thesupernatants were combined and allowed to cool to room temperature,then stored at 2 °C for 5 h. Themixture was filtered, andthe filtered white solid was washed with water and dried undervacuum overnight to give 4-vinylphenylboronic acid (1.10 g,52percent): 1H NMR (500 MHz, DMSO-d6) δ 8.03 (br s, 2H), 7.76(d, 2H, J = 8.2 Hz), 7.42 (d, 2H, J = 8.2 Hz), 6.72 (dd, 1H,J = 17.6, 11.1 Hz), 5.87 (d, 1H, J = 17.6 Hz), 5.28 (d, 1H,J = 11.1 Hz). |